Summary[1] edit edit source
HLB Therapeutics Co.,Ltd. develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmologic diseases, such as dry eye syndrome and neurotrophic keratopathy; GBT-101 for treating epidermolysis bullosa dermal disease; and OKN-007 for the treatment of glioblastoma brain cancer. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components such as motors, pumps, and trances. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
References and notes edit edit source
- ↑ Source: Yahoo Finance.